Condition: Solid Tumor Malignancies, Cancer · Solid Cancers · Solid Tumor Cancer · Sponsor: LaunXP Biomedical Co., Ltd.
A Phase I, open-label, first-in-human study to determine the MTD, recommended phase 2 dose (RP2D), assess the safety, tolerability, pharmacokinetics and preliminary anti-tumor activity of LXP1788 Injection in patients with advanced solid tumor. Patients with advanced solid tumors that are refractory to currently available therapies or for whom no effective treatment is available will be selected. The main questions it aims to answer are: 1. To determine the maximum tolerated dose (MTD) and the recommended phase 2 dose (RP2D) of LXP1788 Injection 2. To evaluate the pharmacokinetics (PK) of LXP1788 Injection
This description comes directly from the study's public registry record.
Chin- Hua Lin Clinical Research Director · +886-4-2320-5691 · rdjulialin@launxp.com
Pin-Hung Kuo · +886-4-2320-5691 · phkuo@launxp.com
Always discuss trial participation with your own doctor first.
| China Medical University Hospital | Taichung, Taiwan | Recruiting |
| National Cheng Kung University Hospital | Tainan, Taiwan | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06883539